2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4065 Deletion 12p is associated with reduced benefit from talquetamab but not BCMA-directed therapy in multiple myeloma

Charles Pei, MD, Michael Lee, MD2, Alessandro La Ferlita3, Francesca Cottini, MD4
1 UT Southwestern Medical Center, Dallas, Texas, United States
2 The Ohio State University, Columbus, Ohio, United States
3 The Ohio State University, Columbus, Ohio, United States
4 The Ohio State University, Columbus, Ohio, United States

Background: GPRC5D, the target of talquetamab, is located within the 12p13 cytoband, a region that is frequently deleted at diagnosis or acquired after therapy in patients with multiple myeloma (MM). Historically, del(12p) has been associated with poor prognosis, in part because of its co-occurrence with other high-risk cytogenetic abnormalities, including del(17p). However, limited data exist regarding its relevance in the era of novel therapies, particularly its potential association with outcomes following GPRC5D-targeted therapy. In this study, we evaluated the prevalence, disease associations, and clinical significance of del(12p) and GPRC5D locus alterations in the MMRF CoMMpass dataset. We also examined the association between del(12p) and outcomes following treatment with talquetamab or BCMA-directed therapies.

Methods: Sequential fluorescence in situ hybridization (seqFISH) data from the MMRF CoMMpass dataset were analyzed to assess associations between del(12p), patient characteristics, concurrent cytogenetic abnormalities, and overall survival (OS). We also evaluated clinical outcomes among patients treated with talquetamab, teclistamab, and ciltacabtagene autoleucel (cilta-cel) at our institution between February 2023 and September 2025. Conventional FISH for del(12p13.2) was performed using a probe from Abbott Molecular. Continuous variables were compared using the Mann-Whitney U test, and categorical variables were compared using Fisher’s exact test. OS and duration of response (DoR) were estimated using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).

Results: Del(12p) was detected at diagnosis in 54 of 627 patients (8.6%) in the CoMMpass dataset. Del(12p) was not associated with age, race, or sex but was enriched among patients with del(17p) (20.7% vs. 7.4%; p = 0.002), del(1p) (18.7% vs. 6.0%; p < 0.0001), and t(4;14) (24.3% vs. 6.5%; p < 0.001). Similar associations were observed for deletions and loss-of-heterozygosity events involving the GPRC5D locus. OS did not differ between patients with and without del(12p) (p = 0.34) or between those with and without GPRC5D loss of heterozygosity (p = 0.141).

Across the treatment cohorts, FISH results were available for 110 patients (21 treated with talquetamab, 41 with teclistamab, and 48 with cilta-cel), of whom 17 (15.5%) had del(12p). Del(12p) showed a trend toward co-occurrence with del(17p) (28.6% vs. 12.1%; p = 0.07), but was not associated with sex, race, or other evaluated cytogenetic abnormalities.

Among the 21 talquetamab-treated patients with evaluable del(12p) results, the median age was 69 years (range, 44–77), and the median number of prior lines of therapy was 7 (range, 3–17). Five patients had previously received CAR T-cell therapy, and eight had previously received a BCMA-directed T-cell engager. Del(12p) was more frequent among patients with concomitant t(4;14). The rate of very good partial response or better was lower among patients with del(12p) than among those without del(12p) (16.7% vs. 73.3%; Fisher’s exact p = 0.029). Among patients who achieved a response, DoR was shorter among patients with del(12p) by log-rank analysis (p = 0.03). In an exploratory Cox model adjusted for t(4;14), del(12p) remained associated with a higher hazard of shorter response duration (HR, 10.39; 95% CI, 2.20-49.14; p = 0.003), although the estimate was imprecise because of the small cohort and limited number of events. In contrast, del(12p) was not associated with inferior response rates or shorter DoR among patients treated with teclistamab (log-rank p = 0.48) or cilta-cel (log-rank p = 0.372).

Conclusion: Del(12p) was associated with other high-risk cytogenetic abnormalities but not with OS in the CoMMpass dataset. In our small exploratory cohort, del(12p) identified a subset of patients with lower response rates and shorter response duration following talquetamab treatment, while no such association was observed with BCMA-directed therapies. Although limited by sample size and number of events, these findings suggest that assessment of del(12p) and GPRC5D locus status may be associated with reduced benefit from talquetamab and warrant further investigation in larger cohorts.

Francesca Cottini, MD: Pfizer - Research Funding; Sanofi - Consultancy (Includes expert testimony)